Trump administration ends Medicare drug subsidy, raising costs for seniors

Seniors in stand-alone Medicare Part D drug plans are set to lose a temporary federal subsidy after 2026, opening the door to higher monthly bills in 2027 for roughly 25 million Americans. The program, the Medicare Part D Premium Stabilization Demonstration, had helped keep premiums stable, and its end could leave some beneficiaries paying more for coverage, with further increases possible in copayments or plan generosity depending on how insurers respond.

The first hit for many older Americans is likely to show up in premium notices for 2027 coverage. CMS said on July 28 that the national average monthly bid amount for Part D plans would be $296.05 and the national base beneficiary premium would be $41.33. For a beneficiary now paying close to that base premium, even a modest increase would add up over a year, before deductibles and prescription copays are counted.

The impact will vary by plan, but the policy change is aimed squarely at stand-alone Part D drug plans, not at an abstract budget line. A retiree who uses several chronic medications could still benefit from the $2,000 annual out-of-pocket cap that took effect in 2025 under the Inflation Reduction Act, yet the end of the subsidy could still make the monthly plan itself more expensive. CMS also has lower prices for 15 negotiated drugs set to begin Jan. 1, 2027, but those savings will not fully offset higher premiums if plan sponsors pass through more costs.

The Trump administration has argued that the temporary subsidy mainly benefited private insurers that offer Part D coverage rather than patients directly. CMS said its July 28 bid release was meant to help plan sponsors finalize their Part D and Medicare Advantage offerings for 2027, when insurers will reset prices without the extra support. KFF said ending the temporary subsidies could mean larger premium increases for some beneficiaries next year.

The policy change also carries clear political and regulatory weight. The U.S. Government Accountability Office published a report on Feb. 26, 2026, on the implementation of the beneficiary premium stabilization demonstration, underscoring that the program was always a temporary measure. With the subsidy ending after 2026, the most visible effects are likely to arrive when 2027 enrollment materials go out and seniors compare higher premiums against the new drug-cost protections already built into Medicare.